Anti-tumor immunity and efficacy of combination treatment of M6223 and bintrafusp alfa versus the combination of M6223 and anti-PD-L1 in preclinical tumor models

被引：0
|
作者：
Xu, Chunxiao [1 ]
Yalavarthi, Sireesha [1 ]
Bourin, Clotilde [1 ]
Kelton, Christie [1 ]
Halle, Joern-Peter [2 ]
Moisan, Jacques [1 ]
机构：
[1] EMD Serono, Billerica, MA USA
[2] Merck KGaA, Healthcare Business, Darmstadt, Germany
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
593
引用
收藏
页数：1
相关论文
共 50 条
  • [1] THE ANTI-TIGIT ANTIBODY M6223 INDUCES SIGNIFICANT ANTI-TUMOR EFFICACY AND IMMUNE RESPONSE VIA MULTIPLE MECHANISMS OF ACTION
    Xu, Chunxiao
    Jiang, Feng
    Huang, Hui
    Webb, Lindsay
    Yalavarthi, Sireesha
    Bourin, Clotilde
    Wang, Hong
    Belousova, Natalya
    Chen, Zhouxiang
    Kelton, Christie
    Zhang, Dong
    Halle, Joern-Peter
    Blaukat, Andree
    Moisan, Jacques
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A351 - A352
  • [2] First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors
    Naing, Aung
    McKean, Meredith
    Tolcher, Anthony
    Victor, Anja
    Hu, Ping
    Mehr, Keyvan Tadjalli
    Kitzing, Thomas
    Holland, Daniel
    Richter, Emilia
    Siu, Lillian
    CANCER RESEARCH, 2024, 84 (07)
  • [3] Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumours
    Siu, L. L.
    Mckean, M. A.
    Tolcher, A. W.
    Victor, A.
    Kitzing, T.
    Pierre, V.
    Gleicher, S.
    Holland, D. G.
    Richter, E.
    Naing, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S887 - S887
  • [4] A FIRST-IN-HUMAN PHASE I STUDY OF M6223 (TIGIT INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH BINTRAFUSP ALFA IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED SOLID UNRESECTABLE TUMORS
    Watson, Geoffrey
    McKean, Meredith
    Tolcher, Anthony
    Victor, Anja
    Zhang, Sen
    Pierre, Vadryn
    Richter, Emilia
    Naing, Aung
    Naing, Aung
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A561 - A561
  • [5] EVALUATION OF NOVEL ANTI-TIGIT ANTIBODY M6223 AS A SINGLE AGENT AND IN COMBINATION WITH AVELUMAB ON HUMAN NATURAL KILLER (NK) CELL CYTOTOXICITY
    Titov, Anton
    Sun, Nancy
    Kelton, Christie
    Jurzak, Mirek
    Ma, Hong
    Xu, Chunxiao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A453 - A453
  • [6] Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models
    Borodovsky, Alexandra
    Wang, Yanjun
    Ye, Minwei
    Shaw, Joseph C.
    Sachsenmeier, Kris
    Deng, Nanhua
    Goodwin, Kelly
    Clarke, James D.
    Goodwin, Richard
    Strittmatter, Nicole
    Hay, Carl
    Sah, Vasu
    Deborah, Lawson
    Reimer, Corinne
    Congreve, Miles
    Mason, Jonathan
    Marshall, Fiona
    Lyne, Paul
    Woessner, Richard
    CANCER RESEARCH, 2018, 78 (13)
  • [7] Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies
    Willingham, Stephen
    Hotson, Andrew
    Ho, Po
    Choy, Carmen
    Walter, Kim
    Yusko, Erik
    Benzeno, Sharon
    Laport, Ginna
    Miller, Richard
    McCaffery, Ian
    CANCER RESEARCH, 2017, 77
  • [8] Unleashing anti-tumor immunity through anti-OX40 monotherapy and in combination with anti-PD-L1
    Kim, Jeong M.
    CANCER RESEARCH, 2015, 75
  • [9] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
    Wang, Sarah
    Sun, Kaiming
    Xiao, Yonghong
    Feng, Bin
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing
    CANCER RESEARCH, 2018, 78 (13)
  • [10] M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
    Knudson, Karin M.
    Hicks, Kristin C.
    Luo, Xiaoling
    Chen, Jin-Qiu
    Schlom, Jeffrey
    Gameiro, Sofia R.
    ONCOIMMUNOLOGY, 2018, 7 (05):
12345